US Stock Price Movement: Xeris Biopharma surged on October 19 following KEVEYIS litigation and endocrine data

Xeris Biopharma October 19th Surge Interpretation

Keywords: KEVEYIS litigation, endocrine data

1. On October 13th, Xeris, through its subsidiary, filed two infringement lawsuits regarding its US patents related to KEVEYIS in the federal district court of New Jersey, accusing relevant companies of infringing patents with their generic dichlorphenamide products and seeking injunctions and damages as remedies.

2. On October 15th, the company announced it will present clinical and scientific data on its commercial products and R&D pipeline at three scientific conferences, including Gvoke for severe hypoglycemia, Recorlev for Cushing's syndrome, and XP-8121 for hypothyroidism.

(Disclaimer: This content is generated by AI technology summarizing publicly available information, for reference only, and does not constitute investment advice.)